No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Poolbeg Pharma updated the market on its potential combination with Hookipa Pharma on Friday, clarifying Gilead Sciences' role in the proposed concurrent fundraise.
The AIM-traded firm said Gilead, which holds existing contractual obligations with Hookipa, had expressed its intention to participate in the fundraise with a contribution of up to $8.7495m.
Additionally, Gilead indicated it would align its vote with the Hookipa board's recommendation if a formal offer was made.
Discussions regarding the potential merger remained non-binding and non-exclusive.
Poolbeg warned that there was no certainty that a firm offer would materialise, or that a transaction would be completed.
At 1545 GMT, shares in Poolbeg Pharma were down 7.14% at 5.2p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.